Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

David Arcella

Anesthesiology Charleston, SC Medical Doctor

NPI 1851652150 CMS profile 1184649

125 Doughty St Ste 420, Charleston, SC 29403

Open in the dashboard

General payments

$17,665

267 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, David Arcella of Charleston, SC is reported in the CMS Open Payments database as having received $17,665 across 267 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Anesthesiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $903 16
2024 General $4,092 32
2023 General $1,588 44
2022 General $5,508 67
2021 General $508 16
2020 General $845 5
2019 General $4,222 87

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • David Arcella
  • Anesthesiology median
  • Middle half of Anesthesiology
  • National median

In program year 2025, general payments to David Arcella were reported at $903. Among 18,548 Anesthesiology profiles paid that year, the median was $58 and the middle half received between $26 and $153.

Show as a table
Year David Arcella Anesthesiology median Middle half National median
2019 $4,222 $72 $23–$151 $163
2020 $845 $36 $17–$120 $114
2021 $508 $49 $21–$135 $132
2022 $5,508 $52 $22–$144 $149
2023 $1,588 $53 $23–$143 $160
2024 $4,092 $55 $25–$150 $164
2025 $903 $58 $26–$153 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $4,928 78 payments
  2. Medtronic USA, Inc. $3,645 46 payments
  3. Nevro Corp. $2,899 10 payments
  4. Spinal Simplicity, LLC $1,402 17 payments
  5. Medtronic, Inc. $1,346 22 payments
  6. Biodelivery Sciences International, Inc. $1,079 25 payments
  7. MML US, Inc. $738 9 payments
  8. Globus Medical, Inc. $328 6 payments
  9. Electronic Waveform Lab, Inc. $187 4 payments
  10. Boston Scientific Corporation $186 11 payments
  11. Other $928 39 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,766 246 payments
  2. Travel and Lodging $5,493 18 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2,610 1 payment
  4. Honoraria $750 1 payment
  5. Education $45 1 payment
Products named General payments · program years 2019–2025
  1. Vyrsa V1 $2,610 1 payment
  2. INTELLIS $1,859 27 payments
  3. PROCLAIM Neuromodulation $1,735 27 payments
  4. PROCLAIM Neuromodulation $1,541 14 payments
  5. HA MINUTEMAN G3-R $1,402 17 payments
  6. OSTEOCOOL RF ABLATION $941 5 payments
  7. BELBUCA $837 5 payments
  8. ReActiv8 $738 9 payments
  9. KYPHON Balloon Kyphoplasty $734 10 payments
  10. ETERNA $524 9 payments
  11. Other $5,083 202 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

149

Median for Anesthesiology: 322

Drug cost

$21,313

Median for Anesthesiology: $8,738

Branded share of claims

16.8%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Belbuca Buprenorphine Hcl Brand 25 $20,281
Gabapentin Generic 78 $786
Cephalexin Generic 25 $132
Furosemide Generic 21 $115

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 74 billing codes

Paid by Medicare

$263,194

Of which drugs: $6,790

Medicare patients

516

Average age 74

Services billed

5,103

290 women, 226 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 34%
Ischemic heart disease 28%
Chronic kidney disease 26%
Depression 25%
Cancer 22%
Atrial fibrillation 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 75 107 $84
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 166 295 $28

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

267 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anesthesiology in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record